RE
SER icon

RBC Europe’s Serina Therapeutics SER Stock Holding History

RBC Europe’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16
Closed -$866 – 1242
2020
Q4 		$866 Hold
16
– – ﹤0.01% 1096
2020
Q3 		$462 Hold
16
– – ﹤0.01% 1058
2020
Q2 		$540 Hold
16
– – ﹤0.01% 1020
2020
Q1 		$530 Hold
16
– – ﹤0.01% 985
2019
Q4 		$1.04K Hold
16
– – ﹤0.01% 988
2019
Q3 		$1.12K Hold
16
– – ﹤0.01% 987
2019
Q2 		$2.09K Hold
16
– – ﹤0.01% 982
2019
Q1 		$2.31K Hold
16
– – ﹤0.01% 992
2018
Q4 		$1.7K Buy
+16
New +$2.03K ﹤0.01% 1008

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

RBC Europe's SER Position: Q1 2021 in Review

RBC Europe sold out of Serina Therapeutics (SER) in Q1 2021, closing a stake of 16 shares — an estimated $866 sold.

RBC Europe first reported a position in SER in Q4 2018 and held it in 9 quarters. The position peaked at $2.31K in Q1 2019. 36 funds tracked by Wall St. Rank hold SER as of Q1 2021.

  • RBC Europe reported no remaining Serina Therapeutics position as of Q1 2021 after selling out during the quarter.
  • RBC Europe sold 16 Serina Therapeutics shares in Q1 2021, an estimated $866.
  • RBC Europe first reported a position in Serina Therapeutics in Q4 2018 and held it in 9 quarters.
  • RBC Europe's Serina Therapeutics position peaked at $2.31K in Q1 2019.
  • 36 funds tracked by Wall St. Rank held Serina Therapeutics as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.